Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes

Thu Oct 24, 2013 5:19pm EDT

* Reuters is not responsible for the content in this press release.

Bristol-Myers Squibb Prices $1.5 Billion of Senior Notes

Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has agreed to sell $1.5 billion of senior unsecured notes: $500,000,000 million in aggregate principal amount of 1.750% notes due 2019, $500,000,000 million in aggregate principal amount of 3.250% notes due 2023 and $500,000,000 million in aggregate principal amount of 4.500% notes due 2044, in an underwritten public offering.

Deutsche Bank Securities Inc., J.P. Morgan Securities LLC, Barclays Capital Inc., BNP Paribas Securities Corp., Credit Suisse Securities (USA) LLC and RBS Securities Inc. are acting as joint book-running managers of the underwriters.

Bristol-Myers Squibb intends to use the net proceeds from the offering for general corporate purposes, including the repayment of all or a portion of its commercial paper borrowings. The offering is expected to close on October 31, 2013, subject to customary closing conditions.

When available, the final prospectus supplement and accompanying prospectus relating to the offering of the notes may be obtained by contacting one of the following joint book-running managers:

  • Deutsche Bank Securities Inc., at: 800-503-4611
  • J.P. Morgan Securities LLC, at: 212-834-4533
  • Barclays Capital Inc., at: 888-603-5847
  • BNP Paribas Securities Corp., at: 800-854-5674
  • Credit Suisse Securities (USA) LLC, at: 800-221-1037
  • RBS Securities Inc., at: 866-884-2071

The final prospectus supplement and accompanying prospectus, when available, may also be accessed through the SEC’s website at www.sec.gov.

These securities are offered pursuant to a registration statement that has become effective under the Securities Act of 1933, as amended. These securities are only offered by means of the prospectus supplement and prospectus relating to the offering. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any offer or sale of these securities in any state or other jurisdiction, where the offer, solicitation or sale of these securities would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol-Myers Squibb's business, including those identified in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2012, particularly under "Item 1A. Risk Factors". Bristol- Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Bristol-Myers Squibb Company
Media:
Laura Hortas, 609-252-4587
laura.hortas@bms.com
or
Investors:
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com
or
Ryan Asay, 609-252-5020
ryan.asay@bms.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.